Search

Learn about research on lymphedema at Memorial Sloan Kettering Cancer Center, which finds that Black and Hispanic women are at highest risk.

… Wednesday, April 3, 2024 Update: Dr Andrea Barrio and colleagues from MSK published a study in JAMA Network in March 2024, which found that Black, Hispanic, and Asian women with breast cancer experience more arm symptoms and worse quality of life than white women after axillary lymph node dissection,

Learn about important advances in the treatment of pancreatic cancer.

… Thursday, June 5, 2025 Many people have questions about pancreatic cancer and its prognosis. MSK surgeon-scientist and pancreatic cancer expert Vinod Balachandran, MD, discusses why the disease is so hard to detect, what the latest treatment options are, and how promising research may improve survival

The Cycle for Survival community, along with founding partner, Equinox, achieves a historic fundraising milestone, fueling rare cancer research at Memorial Sloan Kettering.

… Thursday, April 28, 2022 Cycle for Survival, the movement to beat rare cancers, made history by surpassing $300 million in total funds raised through its signature stationary-cycling events. Since 2007, more than 1 million participants worldwide, including patients, caregivers, survivors, as well as

Learn how MSK uses the watch-and-wait approach to rectal cancer, which can preserve people's quality of life by successfully treating rectal cancer without removing the rectum.

… Friday, February 28, 2025 There’s an alternative for treating some patients with  rectal cancer that makes it possible to avoid  surgical removal of the rectum and the related side effects, which can include changes to sexual function and fertility and the possibility of a permanent ostomy bag — a pouch

Descubra cómo MSK utiliza el enfoque de observación y espera para el cáncer de recto, que permite preservar la calidad de vida de los pacientes al tratar con éxito el cáncer de recto sin necesidad de extirpar el recto.

… Friday, February 28, 2025 Existe una alternativa para tratar a algunos pacientes con cáncer de recto que permite evitar la extirpación quirúrgica del recto y los efectos secundarios relacionados, que pueden incluir cambios en la función sexual y la fertilidad y la posibilidad de tener que usar una bolsa

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.

… Sunday, April 27, 2025 An approach pioneered at Memorial Sloan Kettering Cancer Center (MSK) that caused rectal cancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric) , colon , esophageal

Obtenga información sobre un ensayo clínico en el que se utilizó únicamente inmunoterapia para tratar a personas con varios tipos diferentes de cáncer, lo que significa que no tuvieron que someterse a cirugía, radioterapia ni quimioterapia.

… Sunday, April 27, 2025 Un enfoque en el que Memorial Sloan Kettering Cancer Center (MSK) fue pionero y que hizo que los tumores de cáncer de recto con una mutación genética específica desaparecieran en el 100 % de los participantes en el ensayo clínico se ha ampliado para tratar otros tipos de cáncer

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

… Tuesday, January 29, 2019 Bottom Line: Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD , has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

… Sunday, September 20, 2020 Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease control, which means that their tumors stopped growing. Update: On January 30, 2021, Memorial Sloan Kettering lung cancer expert Bob

An MSK program helps lung cancer survivors stay healthy following successful treatment for their disease.

… Tuesday, December 10, 2024 Summary With more people surviving longer after lung cancer , close management of those who have had successful treatment is more important than ever. MSK’s Lung Cancer Survivorship Program provides regular screening for recurrent cancers or new tumors, as well as guidance